Tyme (TYME) 10-K 12 Jun 19 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2019	Jun. 04, 2019	Sep. 30, 2018
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Trading Symbol	TYME
Entity Registrant Name	TYME TECHNOLOGIES, INC.
Entity Central Index Key	0001537917
Current Fiscal Year End Date	--03-31
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		111,950,937
Entity Public Float			$ 137,958,473

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Current assets
Cash and cash equivalents	$ 14,302,328	$ 28,975,822
Prepaid rent	242,755	6,450
Prepaid clinical costs	592,134	149,400
Prepaid expenses and other current assets	1,001,898	616,905
Total current assets	16,139,115	29,748,577
Property and equipment, net	10,363	3,239
Prepaid rent, net of current portion	101,148
Prepaid clinical costs, net of current portion	1,266,025	1,266,025
Total assets	17,516,651	31,017,841
Current liabilities
Accounts payable and other current liabilities (including $325,000 and $384,000 of related party accounts payable, respectively)	3,692,308	2,817,090
Severance payable	523,261
Accrued bonuses	1,495,248	1,248,690
Insurance note payable	597,339	480,094
Total current liabilities	6,308,156	4,545,874
Long-term liabilities
Severance payable	1,540,613
Total liabilities	7,848,769	4,545,874
Commitments and contingencies (See Note 9)
Stockholders’ equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding
Common stock, $0.0001 par value, 300,000,000 shares authorized, 103,946,048 issued and outstanding at March 31, 2019, and 300,000,000 authorized, 101,226,479 issued and outstanding at March 31, 2018	10,397	10,125
Additional paid in capital	95,472,181	79,293,423
Accumulated deficit	(85,814,696)	(52,831,581)
Total stockholders’ equity	9,667,882	26,471,967
Total liabilities and stockholders’ equity	$ 17,516,651	$ 31,017,841

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized	10,000,000	10,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized	300,000,000	300,000,000
Common stock, issued	103,946,048	101,226,479
Common stock, outstanding	103,946,048	101,226,479
Drinker, Biddle & Reath LLP ("DBR") [Member]
Related party accounts payable	$ 325,000	$ 384,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended								12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2019	Mar. 31, 2018
Operating expenses:
Research and development	$ 3,740,049	$ 4,525,228	$ 3,443,516	$ 3,010,688	$ 2,437,392	$ 2,585,991	$ 2,551,920	$ 1,264,358	$ 14,719,481	$ 8,839,661
General and administrative (including $977,000 and $1,619,000 of related party legal expenses, respectively)	3,758,287	3,550,223	3,569,174	3,708,481	2,875,741	2,975,274	2,744,998	1,924,204	14,586,165	10,520,217
Severance expense	2,470,906								2,470,906
Total operating expenses	9,969,242	8,075,451	7,012,690	6,719,169	5,313,133	5,561,265	5,296,918	3,188,562	31,776,552	19,359,878
Loss from operations	(9,969,242)	(8,075,451)	(7,012,690)	(6,719,169)	(5,313,133)	(5,561,265)	(5,296,918)	(3,188,562)	(31,776,552)	(19,359,878)
Warrant modification expense	(1,289,125)								(1,289,125)
Other income, net	61,122	27,497	(2,430)	(3,627)					82,562	390,385
Loss before income taxes	(11,197,245)	(8,047,954)	(7,015,120)	(6,722,796)	(5,313,133)	(5,561,265)	(5,222,157)	(2,872,938)	(32,983,115)	(18,969,493)
Net loss	$ (11,197,245)	$ (8,047,954)	$ (7,015,120)	$ (6,722,796)	$ (5,313,133)	$ (5,561,265)	$ (5,222,157)	$ (2,872,938)	$ (32,983,115)	$ (18,969,493)
Basic and diluted loss per common share	$ (0.10)	$ (0.08)	$ (0.07)	$ (0.07)	$ (0.06)	$ (0.06)	$ (0.06)	$ (0.03)	$ (0.32)	$ (0.21)
Basic and diluted weighted average shares outstanding	103,546,379	103,009,449	101,647,555	101,226,479	93,829,568	89,929,161	89,321,067	89,258,377	102,354,050	90,567,476

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Parenthetical) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Related party legal expenses	$ 977,000	$ 1,619,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Total	Private Placement Offering [Member]	ATM Financing Facility [Member]	Public Offering [Member]	Common Stock [Member]	Common Stock [Member]Private Placement Offering [Member]	Common Stock [Member]ATM Financing Facility [Member]	Common Stock [Member]Public Offering [Member]	Common Stock Subscribed [Member]	Additional Paid-in capital [Member]	Additional Paid-in capital [Member]Private Placement Offering [Member]	Additional Paid-in capital [Member]ATM Financing Facility [Member]	Additional Paid-in capital [Member]Public Offering [Member]	Subscription Receivable [Member]	Accumulated Deficit [Member]
Balance, at beginning at Mar. 31, 2017	$ 7,391,806				$ 9,172				$ 6	$ 41,419,714				$ (174,998)	$ (33,862,088)
Balance, at beginning (in shares) at Mar. 31, 2017					91,692,641				58,823
Issuance of common stock and warrants in private placement offering for cash, net of associated expense		$ 2,597,100				$ 107					$ 2,596,993
Issuance of common stock and warrants in private placement offering for cash, net of associated expense (in shares)						1,069,603
Issuance of common stock			$ 5,824,017	$ 21,740,460			$ 154	$ 1,035				$ 5,823,863	$ 21,739,425
Issuance of common stock (in shares)			1,543,364	10,350,000			1,543,364	10,350,000
Proceeds from collection of stock subscription receivable	174,998				$ 6				$ (6)					$ 174,998
Proceeds from collection of stock subscription receivable (in shares)					58,823				(58,823)
Stock based compensation	7,689,334									7,689,334
Issuance of common stock upon exercise of options and warrants	35,530				$ 1					35,529
Issuance of common stock upon exercise of options and warrants (in shares)					12,048
Derivative liability	(11,785)									(11,785)
Retirement and cancellation of shares of common stock					$ (350)					350
Retirement and cancellation of shares of common stock (in shares)					(3,500,000)
Net loss	(18,969,493)														(18,969,493)
Balance, at end at Mar. 31, 2018	$ 26,471,967				$ 10,125					79,293,423					(52,831,581)
Balance, at end (in shares) at Mar. 31, 2018	101,226,479				101,226,479
Issuance of common stock			$ 5,668,244				$ 238					$ 5,668,006
Issuance of common stock (in shares)			2,383,884				2,383,884
Exercise of options	$ 270,000				$ 10					269,990
Exercise of options (in shares)	100,000				100,000
Cashless exercise of warrants					$ 24					(24)
Cashless exercise of warrants (in shares)					235,685
Warrant modification	$ 1,289,125									1,289,125
Severance stock based compensation	388,282									388,282
Stock based compensation	8,563,379									8,563,379
Net loss	(32,983,115)														(32,983,115)
Balance, at end at Mar. 31, 2019	$ 9,667,882				$ 10,397					$ 95,472,181					$ (85,814,696)
Balance, at end (in shares) at Mar. 31, 2019	103,946,048				103,946,048

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Parenthetical)	12 Months Ended
	Mar. 31, 2018USD ($)
Private Placement Offering [Member]
Offering expense	$ 130,300
ATM Financing Facility [Member]
Offering expense	327,939
Public Offering [Member]
Offering expense	$ 1,547,972

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net loss	$ (32,983,115)	$ (18,969,493)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	8,420	4,296
Amortization of employees, directors and consultants stock options	8,563,379	7,689,334
Warrant modification expense	1,289,125
Severance stock based compensation	388,282
Gain on remeasurement of derivative liability		(390,385)
Changes in operating assets and liabilities:
Prepaid rent	(337,453)	(6,450)
Prepaid clinical costs	(442,734)	(1,415,425)
Prepaid and other assets	433,334	91,551
Accounts payable and other current liabilities	654,229	(131,378)
Severance payable	2,063,874
Accrued bonuses	246,558	1,248,690
Net cash used in operating activities	(20,116,101)	(11,879,260)
Cash flows from investing activities:
Purchase of property & equipment	(15,544)
Net cash used in investing activities	(15,544)
Cash flows from financing activities:
Insurance note payments	(480,093)
Issuance of common stock from at-the-market financing facility (net of expenses)	5,668,244	5,824,017
Proceeds from exercise of stock options	270,000	35,530
Proceeds from private placement offering of common stock and warrants, net of issuance costs		2,597,100
Proceeds from the collection of stock subscription receivable		174,998
Proceeds from public offering, net of issuance of costs		21,740,460
Net cash provided by financing activities	5,458,151	30,372,105
Net (decrease) increase in cash	(14,673,494)	18,492,845
Cash and cash equivalents — beginning of year	28,975,822	10,482,977
Cash and cash equivalents — end of year	14,302,328	28,975,822
Cash paid for interest and income taxes are as follows:
Interest	7,415
Noncash investing and financing activities:
Financing of insurance premiums	597,339	480,094
Deferred expenses related to post year end financing	$ 220,988
Derivative liability associated with the price protection feature of shares of common stock issued		11,785
Retirement and cancellation of shares of common stock		$ 350

Consolidated Statement of Cas_2

Consolidated Statement of Cash Flows (Parenthetical)	12 Months Ended
	Mar. 31, 2019shares
Statement Of Cash Flows [Abstract]
Cashless exercise of warrants	1,086,271
Cashless exercise of shares of common stock	235,685

Nature of Business

Nature of Business	12 Months Ended
	Mar. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of Business	Note 1. Nature of Business Tyme Technologies, Inc. (“Tyme Tech”) is a Delaware corporation headquartered in New York, NY, with wholly owned subsidiaries, Tyme Inc. and Luminant Biosciences, LLC (“Luminant”) (collectively, “TYME” or the “Company”). Prior to 2014, Luminant conducted the initial research and development of the Company’s therapeutic platform. Since January 1, 2014, the majority of the Company’s research, development and other business activities have been conducted by Tyme Inc., which was incorporated in Delaware in 2013. TYME is an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs TM The Company’s lead clinical CMBT program, SM-88 (racemetyrosine), is a novel, oral, monotherapy investigational agent that has been studied in clinical trials for over five years within more than 150 cancer patients. TYME recently completed enrollment for two Phase II clinical trials in prostate and pancreatic cancer, and the Company is preparing for pivotal studies for SM-88 in pancreatic cancer during the second half of calendar year 2019. One of these pivotal trials is focused on patients with third-line pancreatic cancer and would be an amendment to the ongoing TYME-88-Panc trial (Part 2). The Company has also partnered with the Pancreatic Cancer Action Network (“PanCAN”) to study SM-88 in an adaptive pivotal trial known as Precision Promise SM The accompanying consolidated financial statements include the results of operations of Tyme Tech and its wholly owned subsidiaries. Liquidity The consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has historically funded its operations primarily through equity offerings. During fiscal year 2019, the Company raised gross proceeds of approximately $5.8 million through the issuance of its common stock. Most recently in April 2019, the Company raised net proceeds of $11.3 million after underwriting discounts and before expenses through an underwritten registered offering. Previously on November 2, 2017, the Company entered into an equity distribution agreement (“Equity Distribution Agreement”) with Canaccord Genuity Inc. (“Canaccord”), to commence an at-the-market offering (the “ATM Financing Facility”) pursuant to which the Company may, from time to time, subject to certain rules and regulations, sell shares of the Company’s common stock, par value $0.0001 per share, having an aggregate offering price up to $30.0 million, through Canaccord, as the Company’s sales agent. In the year ended March 31, 2019, the Company raised approximately $5.8 million in aggregate gross proceeds before commissions and expenses through the ATM Financing Facility and paid Canaccord aggregate commissions of $0.2 million. At March 31, 2019, there remained approximately $17.9 million of availability to sell shares through the facility. The proceeds of those offerings are being used by the Company for continued clinical studies, drug commercialization and development activities and other general corporate and operating expenses. For the year ended March 31, 2019, the Company had negative cash flow from operations of $20.1 million and net loss of $33.0 million, which included $10.2 million of non-cash expenses, primarily non-cash equity compensation and warrant modification expense. As of March 31, 2019, the Company had working capital of approximately $9.8 million. Management has concluded that substantial doubt does not exist regarding the Company’s ability to satisfy its obligations as they come due during the twelve-month period following the issuance of these financial statements. This conclusion is based on the Company’s assessment of qualitative and quantitative conditions and events, considered in aggregate as of the date of issuance of these financial statements that are known and reasonably knowable. Among other relevant conditions and events, the Company has considered its operational plans, liquidity sources, obligations due or expected, funds necessary to maintain the Company’s operations, and potential adverse conditions or events as of the issuance date of these financial statements.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies	Note 2. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Significant Accounting Policies Principles of Consolidation The Company’s consolidated financial statements include the accounts of Tyme Tech and its subsidiaries, Tyme, Inc. and Luminant. All intercompany transactions and balances have been eliminated in consolidation. Risks and Uncertainties The Company is subject to those risks associated with any specialty pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants, as well as third party contractors. Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Significant items subject to such estimation include the calculation of the stock-based compensation. Actual results could differ from such estimates. Cash and Cash Equivalents The Company considers all highly-liquid investments that have maturities of three months or less when acquired to be cash equivalents. At March 31, 2019 and 2018, the Company did not have any cash equivalents. The Company’s cash and cash equivalents consisted of $14.3 million at March 31, 2019 and $29.0 million at March 31, 2018. Concentration of Credit Risk Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash. Cash is deposited with major banks and, at times, such balances with any one financial institution may be in excess of FDIC insurance limits. The Company exceeded the FDIC limit of $250,000 by $14.0 million at March 31, 2019 and $28.7 million at March 31, 2018. Although the Company has exceeded the federally insured limit, it has not incurred losses related to these deposits. Management monitors the Company’s accounts with these institutions to minimize credit risk. Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments, including cash, accounts payable and other current liabilities approximates fair value given their short-term nature. The fair value of the severance payable approximates the carrying value, which represents the present value of future severance payments. The fair value of the derivative liability is discussed below. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value should be based on the assumptions that market participants would use when pricing an asset or liability and is based on a fair value hierarchy that prioritizes the information used to develop those assumptions. The fair value hierarchy gives the highest priority to quoted prices in active markets (observable inputs) and the lowest priority to the Company’s assumptions (unobservable inputs). Fair value measurements should be disclosed separately by level within the fair value hierarchy. For assets and liabilities recorded at fair value, it is the Company’s policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with established fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no observable market data are based primarily upon estimates, and often are calculated based on the economic and competitive environment, the characteristics of the asset or liability and other factors. Therefore, the results cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any calculation technique, and changes in the underlying assumptions used, including discount rates and estimates of future cash flows, could significantly affect the results of current or future values. Additionally, from time to time, the Company may be required to record at fair value other assets on a nonrecurring basis, such as assets held for sale and certain other assets. These nonrecurring fair value adjustments typically involve application of lower-of-cost-or-market accounting or write-downs of individual assets. Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: • Level 1 — Quoted prices in active markets for identical assets or liabilities. • Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 valuations are for instruments that are not traded in active markets or are subject to transfer restrictions and may be adjusted to reflect illiquidity and/or non-transferability, with such adjustment generally based on available market evidence. In the absence of such evidence, management’s best estimate is used. An adjustment to the pricing method used within either Level 1 or Level 2 inputs could generate a fair value measurement that effectively falls in a lower level in the hierarchy. The Company had no assets or liabilities classified as Level 1, Level 2, or Level 3 for the year ended March 31, 2019 and 2018. There were no transfers between Level 1, Level 2 and Level 3 in any of the periods reported. The changes in the fair value of the derivative liabilities for the year ended March 31, 2018 are as follows: Fair value at March 31, 2017 $ 378,600 Fair value of liability-classified anti-dilution feature 11,785 Change in fair value of derivative liability (390,385 ) Fair value at March 31, 2018 $ — Prepaid and Other Current Assets Prepaid expenses represent expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time. Prepaid and other current assets includes $0.6 million and $0.5 million of prepaid insurance as of March 31, 2019 and 2018, respectively. Property and Equipment, Net Property and equipment are recorded at cost and are depreciated on a straight-line basis over their estimated useful lives. The Company estimates a life of five to seven years for equipment and furniture and fixtures. Upon sale or retirement, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in results of operations. Repairs and maintenance costs are expensed as incurred. Impairment of Long-Lived Assets The Company assesses the recoverability of its long-lived assets, which include fixed assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine whether the asset’s value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the years ended March 31, 2019 and 2018, the Company determined that there were no triggering events requiring an impairment analysis. Research and Development Research and development costs are expensed as incurred and are primarily comprised of, but not limited to, external research and development expenses incurred under arrangements with third parties, such as contract research organizations (“CROs”), contract manufacturing organizations (“CMOs”) and consultants that conduct clinical and preclinical studies, costs associated with preclinical and development activities, costs associated with regulatory operations, depreciation expense for assets used in research and development activities and employee related expenses, including salaries and benefits for research and development personnel. Costs for certain development activities, such as clinical studies, are accrued, over the service period specified in the contract and recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the patterns of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued expense. Income Taxes Income tax expense, deferred tax assets and liabilities, and liabilities for unrecognized tax benefits reflect management’s best estimate of current and future taxes to be paid. The Company is subject to income taxes in the United States, for federal and various state jurisdictions. Significant judgments and estimates are required in the determination of the income tax expense. Deferred income taxes arise from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements, which will result in taxable or deductible amounts in the future. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided when, after consideration of available positive and negative evidence that it is not more likely than not that the benefit from deferred tax assets will be realizable. In recognition of this risk, we have provided a full valuation allowance against the net deferred tax assets. The assumptions about future taxable income require the use of significant judgment and are consistent with the plans and estimates we are using to manage the underlying businesses. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). The calculation of tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in various jurisdictions. ASC 740 “Income Taxes” states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits. When and if the Company were to recognize interest and penalties related to unrecognized tax benefits, they would be reported in tax expense. Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment. Derivative Liabilities Accounting standards require presentation of derivative liabilities at fair value. Derivative liabilities are adjusted to reflect fair value at the end of each reporting period, with any change in the fair value being recorded in results of operations as a component of other income or expense. Derivative Liability - PPO The Company had recorded a derivative liability related to an anti-dilution provision as part of a 2014 financing agreement. That anti-dilution provision was determined to be a freestanding financial instrument that was carried as a liability at fair value of $0.4 million. During the year ended March 31, 2018 the anti-dilution provision expired without the triggering of any such protection. Accordingly, as of March 31, 2018 and thereafter, there was no fair value of the derivative liability . Basic and Diluted Loss Per Share The Company calculates net loss per share in accordance with ASC Topic 260, “Earning per Share.” Basic net loss per share is computed by dividing net loss attributable to the Company by the weighted average number of shares of Company common stock outstanding for the period, and diluted earnings per share is computed by including common stock equivalents outstanding for the period. During the periods presented, the calculation excludes any potential dilutive common shares and any equivalents as they would have been anti-dilutive as the Company incurred losses for the periods then ended. Stock-based Compensation The Company follows the authoritative guidance for accounting for stock-based compensation in ASC 718, Compensation-Stock Compensation. The guidance requires that stock-based payment transactions be recognized in the financial statements based on their fair value at the grant date and recognized as compensation expense over the vesting period as services are being provided. (See Note 11, Equity Incentive Plan.) The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected The Company accounted for stock-based awards issued to non-employees in accordance with ASC 505-50, “Equity-Based Payment to Non-Employees” and accordingly the fair value of the stock options granted to non-employees was remeasured each reporting period until the earlier of: a) the performance commitment date, or b) the date the services required under the arrangement have been completed and the resulting increase or decrease in value, if any, was recognized as expense or income, respectively, during the period the related services are rendered. Effective July 1, 2018, the Company adopted ASU 2018-07 and, as such, the fair value options granted to non-employees is estimated at the date of grant only. Reclassification Certain prior year amounts have been reclassified to conform to the current year presentation. Recently Adopted Accounting Pronouncements In June 2018, the FASB issued ASU 2018-07, which simplifies the accounting for share-based payments made to nonemployees so that the accounting for such payments is substantially the same as those made to employees, with certain exceptions. Under this ASU, equity-classified share based awards to nonemployees will be measured at fair value on the grant date of the awards, entities will need to assess the probability of satisfying performance conditions if any are present, and awards will continue to be classified according to ASC 718 upon vesting which eliminates the need to reassess classification upon vesting, consistent with awards granted to employees, unless the award is modified after the service has been rendered, any other conditions necessary to earn the right to benefit from the instruments have been satisfied, and the nonemployee is no longer providing services. The Company elected to early adopt ASU 2018-07 effective July 1, 2018. In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718) - Scope of Modification Accounting In February 2017, the FASB issued Update No. 2017-05, Other Income-Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets In January 2017, the FASB issued ASU 2017-01, amending Business Combinations: Clarifying the Definition of a Business In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10), Recognition and Measurement of Financial Assets and Financial Liabilities Recent Accounting Pronouncements In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842)

Net Loss Per Common Share

Net Loss Per Common Share	12 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Net Loss Per Common Share	Note 3. Net Loss Per Common Share The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated: Year Ended March 31, 2019 2018 Basic and diluted net loss per common share calculation Net loss $ (32,983,115 ) $ (18,969,493 ) Weighted average common shares outstanding — basic and diluted 102,354,050 90,567,476 Net loss per share of common stock — basic and diluted $ (0.32 ) $ (0.21 ) The following outstanding securities at March 31, 2019 and 2018 have been excluded from the computation of diluted weighted average shares outstanding, as they would have been anti-dilutive: Year Ended March 31, 2019 2018 Stock options 8,953,527 5,438,072 Warrants 4,499,603 5,585,874 Total 13,453,130 11,023,946

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Mar. 31, 2019
Property Plant And Equipment [Abstract]
Property and Equipment, Net	Note 4. Property and Equipment, Net. Property and equipment, net consisted of the following: March 31, 2019 March 31, 2018 Machinery and equipment $ 37,007 $ 21,463 Less: accumulated depreciation 26,644 18,224 $ 10,363 $ 3,239 Depreciation expense was $8,420 and $4,296 for the years ended March 31, 2019 and 2018, respectively.

Accounts Payable and Other Curr

Accounts Payable and Other Current Liabilities	12 Months Ended
	Mar. 31, 2019
Payables And Accruals [Abstract]
Accounts Payable and Other Current Liabilities	Note 5. Accounts Payable and Other Current Liabilities. Accounts payable and other current liabilities consisted of the following: March 31, 2019 March 31, 2018 Legal $ 602,129 $ 421,261 Consultant and professional services 170,257 134,324 Accounting and auditing 331,119 81,652 Research and development 1,907,787 1,678,675 Board of Directors and Scientific Advisory Board Compensation 489,393 442,610 Other 191,623 58,568 $ 3,692,308 $ 2,817,090

Severance Payable

Severance Payable	12 Months Ended
	Mar. 31, 2019
Severance Payable [Abstract]
Severance Payable	Note 6. Severance Payable On March 15, 2019 the Company entered into a Release Agreement related to the separation of employment of their Chief Operating Officer. The Agreement provides for salary continuance for five years, reimbursement of health benefits for three years and a modification to his outstanding stock options to extend the post-termination exercise period for his vested options from three months to five years. The Company recorded severance expense at its present value of $2.5 million, (using a discount rate of 6%) for the year ended March 31, 2019, including $0.4 million relating to the stock option modification. The severance liability payable as of March 31, 2019 was $2.1 million.

Debt

Debt	12 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Debt	Note 7. Debt. Insurance Note Payable During the years ended March 31, 2019 and 2018, the Company entered into a short-term financing arrangement with its insurance carrier related to payment of premium for its Director and Officer liability insurance coverage totaling $0.6 million and $0.5 million for the policy years ending on March 31, 2019 and 2018, respectively. As of March 31, 2019 and March 31, 2018, there remained a balance of $0.6 million and $0.5 million, respectively, recorded to Insurance note payable on the accompanying consolidated balance sheets.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Stockholders' Equity	Note 8. Stockholders’ Equity. Preferred Stock The Company is authorized to issue up to 10,000,000 shares of preferred stock, each with a par value of $0.0001. Shares of Company preferred stock may be issued from time to time in one or more series and/or classes, each of which will have such distinctive designation or title as shall be determined by the Company’s Board of Directors (“Board”) prior to the issuance of any shares of such series or class. The Company preferred stock will have such voting powers, full or limited or no voting powers and such preferences and relative, participating, optional or other special rights and such qualifications, limitations or restrictions thereof, as shall be stated in such resolution or resolutions providing for the issue of such series or class of Company preferred stock as may be adopted from time to time by the Company’s Board prior to the issuance of any shares thereof. No shares of Company preferred stock are currently issued or outstanding and the Company’s board of directors has not designated any class or series of Company preferred stock for use in the future. Common Stock Voting Each holder of Company common stock is entitled to one vote for each share thereof held by such holder at all meetings of stockholders (and written action in lieu of meetings). The number of authorized shares of Company common stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of majority of the combined number of issued and outstanding shares of the Company. Dividends Dividends may be declared and paid on the Company common stock from funds lawfully available therefore, as and when determined by the Board. Liquidation In the event of the liquidation, dissolution, or winding-up of the Company, holders of Company common stock will be entitled to receive all assets of the Company available for distribution to its stockholders. March 2017 PPO On March 10, 2017, the Company raised $9.2 million in gross proceeds through a private placement (“March 2017 Private Placement”) of 3,588,620 shares of our common stock and 3,588,620 common stock purchase warrants (each, a “Warrant”). Each Warrant entitles its holder to purchase one share of common stock (each, a “Warrant Share”) at an exercise price of $3.00 per Warrant Share, subject to adjustment. The warrants expire two years from the date of issuance and vest immediately. On March 15, 2019, the Board extended the expiration date of the 3,245,288 outstanding warrants through September 30, 2019. April 2017 PPO In April 2017, the Company raised $2.7 million in gross proceeds through a private placement (“April 2017 Private Placement”) of 1,069,603 shares of common stock and 1,069,603 common stock purchase warrants (each, a “Warrant”). Each Warrant entitles its holder to purchase one share of common stock (each, a “Warrant Share”) at an exercise price of $3.00 per Warrant Share. The warrants expire two years from the date of issuance and vest immediately. On March 15, 2019, the Board extended the expiration date of the 238,233 outstanding warrants through September 30, 2019. The Company considers the extensions to be a modification of the March 2017 Private Placement and April 2017 Private Placement warrants. The Company recognized a warrant modification expense of $1.3 million for the year ended March 31, 2019, which represents the incremental value of the modified warrant as compared to the original warrant, both valued on the modification dates which is reflected in warrant modification expense in the consolidated statement of operations. The warrants were valued using the Black-Scholes option-pricing model on the date of the modification using the following assumptions: (a) fair value of common stock $2.31, (b) expected life of 1 and At March 31, 2019, 4,469,836 common stock purchase warrants relating to securities purchase agreements were outstanding and exercisable. The following summarizes the common stock warrant activity for the years ended March 31, 2019 and March 31, 2018: Warrant Shares of Common Stock Weighted Average Exercise Price Outstanding at March 31, 2017 4,526,271 $ 3.42 Granted 1,069,603 3.00 Exercised (10,000 ) 3.00 Cancelled — — Outstanding at March 31, 2018 5,585,874 3.34 Granted — — Exercised (1,086,271 ) 3.00 Cancelled — — Outstanding at March 31, 2019 4,499,603 $ 3.42 During the year ended March 31, 2019, 1,086,271 warrants were exercised on a cashless basis resulting in the issuance of 235,685 shares. At-the-Market Financing Facility On November 2, 2017, the Company entered into an equity distribution agreement (“Equity Distribution Agreement”) with Canaccord Genuity Inc. (“Canaccord”), to commence an at-the-market offering (the “ATM Financing Facility”) pursuant to which the Company may, from time to time, subject to certain rules and regulations, sell shares of the Company’s common stock, par value $0.0001 per share, having an aggregate offering price up to $30 million, through Canaccord, as the Company’s sales agent. In the year ended March 31, 2018, the Company raised approximately $6.2 million in gross proceeds through the ATM via sale of 1,543,364 of our common stock. The Company incurred $0.3 million of related costs which offset the proceeds. In the year ended March 31, 2019, the Company raised approximately $5.8 million in gross proceeds through the ATM via sale of 2,383,884 shares of our common stock. The Company incurred $0.2 million of related costs which offset the proceeds. At March 31, 2019, there remained approximately $17.9 million of availability to sell shares through the facility. Under the ATM Financing Facility, the Company is not required to issue the full available amount authorized and it may be cancelled at any time. Public Offering In March 2018, we raised approximately $23.3 million in gross proceeds through a public offering of 10,350,000 shares of our common stock. The Offering was made pursuant to the Company’s registration statement on Form S-3 (Registration No. 333-211489), which was declared effective by the U.S. Securities and Exchange Commission on August 16, 2017, a base prospectus dated August 16, 2017 and a prospectus supplement dated March 1, 2018.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Mar. 31, 2019
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9. Commitments and Contingencies. Contract Service Providers In the course of the Company’s normal business operations, it enters into agreements and arrangements with contract service providers to assist in the performance of its research and development and clinical research activities. Purchase Commitments The Company has entered into three contracts with manufacturers to supply certain components used in SM-88 in order to achieve favorable pricing on supplied products. These contracts have non-cancellable elements related to the scheduled deliveries of these products in future periods. Payments are made by us to the manufacturer when the products are delivered and of acceptable quality. The contracts are structured to match clinical supply needs for our ongoing trials and we expect the timing of associated payments to predominately occur during fiscal year 2020. Total outstanding future obligations associated with the contracts were $2.0 million at March 31, 2019. In May 2019, the Company increased the work scope of one of the contracts resulting in a commitment increase of $495,000. Leases The Company has a two-year lease for office space in New Jersey with a monthly rent of $2,289 for the first six months and $4,292 for the remaining term expiring February 2021. Future rent payments are $40,000 and $47,000 for fiscal years 2020 and 2021, respectively. The Company has a two-year lease for office furniture in New Jersey with future rent payments of $19,000 and $17,000 for fiscal years 2020 and 2021, respectively. The Company subleases office space in New York, the rent obligation has been prepaid through August 30, 2020. Rent expense, primarily for the New York office, including short term rentals was approximately $243,000 and $93,000 for the years ended March 31, 2019 and 2018 respectively. Legal Proceedings From time to time, the Company may be involved in litigation, claims or other contingencies arising in the ordinary course of business. The Company would accrue a liability when a loss is considered probable and the amount can be reasonably estimated. When a material loss contingency is reasonably possible but not probable, the Company would not record a liability, but instead would disclose the nature and the amount of the claim, and an estimate of the loss or range of loss, if such estimate can be made. Legal fees are expensed as incurred. The Company is not currently a party to any material legal proceedings and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on us, our business, operating results or financial condition.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	Note 10. Related Party Transactions. Legal Drinker Biddle & Reath LLP (“DBR”) has provided legal services to the Company. A partner of DBR was a member of the Board and had received, and was entitled to receive in the future, cash compensation payable to non-employee directors and equity compensation payable to non-employee directors generally under the 2016 Director Plan. See Note 11, Equity Incentive Plan. On September 10, 2018, the Company entered into an employment agreement with the partner and he was appointed as the Company’s Chief Legal Officer and Secretary. He ceased to be a non-employee director on September 10, 2018 and he resigned as a member of the Board effective September 30, 2018. On September 1, 2018, the partner resigned from the partnership of DBR and he assumed a consulting role as “Of Counsel” with the firm.

Equity Incentive Plan

Equity Incentive Plan	12 Months Ended
	Mar. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity Incentive Plan	Note 11. Equity Incentive Plan. On March 5, 2015, the Company’s Board adopted and the Company’s stockholders approved, the Company’s 2015 Equity Incentive Plan (the “2015 Plan”). No more than an aggregate of 3,333,333 shares of common stock may be awarded during the twelve month period starting March 5 of each succeeding year. Awards under the 2015 Plan may include, but need not be limited to, one or more of the following: options, stock appreciation rights, restricted stock, performance grants, stock bonuses, and any other type of award deemed by the administrator to be consistent with the purposes of the 2015 Plan. The exercise price of all options awarded under the 2015 Plan must be no less than 100% of the fair market value of the Company common stock as determined on the date of the grant and have a term of no greater than ten years from the date of grant. In February 2018, the 2015 Plan was amended making available 12.5% of shares of common stock issued and outstanding. As of March 31, 2019, there were 5,262,531 shares available for grant under the 2015 Plan. On August 23, 2018 the stockholders approved the Amended and Restated 2016 Stock Option Plan for Non-Employee Directors (the “2016 Director Plan”), which: (i) increased the total number of shares of Common Stock authorized and reserved for issuance under the 2016 Director Plan by 2,000,000 shares to 2,750,000 shares: (ii) made “Initial Grants” upon a director’s initial appointment to the Board consisting of an immediate stock option grant of 100,000 shares at fair market value; and (iii) made “Annual Grants” for members who continue in service as members of the Board subsequent to each annual meeting of stockholders occurring subsequent to an Initial Grant, an annual stock option grant of 50,000 shares at fair market value. The Initial Grants and Annual Grants have a ten year term, subject to applicable termination or forfeiture provisions, and vest in equal quarterly increments over a one-year period from the date of grant. As of March 31, 2019, there were 1,425,150 shares available for grant under the 2016 Director Plan. Stock Options As of March 31, 2019, and 2018, there was approximately $7.3 million and $9.6 million, respectively, of total unrecognized compensation related to non-vested stock options. The cost is expected to be recognized over the remaining weighted average remaining service period of 1.2 years. During the years ended March 31, 2019 and 2018, the Company had stock compensation expense of $9.0 million and $7.7 million, respectively. For the year ended March 31, 2019, stock compensation expense is recognized as $5.7 million in general and administrative expense, $2.9 million in research and development expense, and $0.4 million in severance expense. For the year ended March 31, 2018, stock compensation expense has been recognized as $4.1 million in general and administrative expense and $3.6 million in research and development expense. The Company uses the Black-Scholes option pricing model to determine the fair value of stock options granted. In accordance with ASC 718, the compensation expense for employees and non-employees is amortized on a straight-line basis over the requisite service period, which approximates the vesting period. The Company accounts for forfeitures as they occur, rather than estimating forfeitures as of an award’s grant date. The expected volatility of options granted has been determined using the method described under ASC 718 using the expected volatility of similar companies. The expected term of options granted to employees and directors in the current fiscal period has been based on the term by using the simplified “plain-vanilla” method as allowed under SAB No. 110. The expected term of options granted to non-employees and consultants is based on the grant’s full contractual life. The Company considered other methods to estimate expected term other than the simplified method. However, as noted above, there is no historical exercise data to provide a reasonable basis upon which to estimate expected term due to the limited period of time its equity shares have been publicly traded and no other refined estimate of expected life that is appropriate. The assumptions utilized to estimate the fair value of stock options granted are presented in the following table: Year Ended March 31, 2019 2018 Risk free interest rate 2.24%-3.10% 1.74%-2.70% Expected volatility 71.86%-76.31% 65.95%-90.32% Expected term 3-6.5 years 1-10 years Dividend yield 0.0% 0.0% The following is a summary of the activity of the Company’s stock options under the 2015 Plan and 2016 Director Plan as of March 31, 2019: Number of Options Weighted Average Exercise Price Outstanding at March 31, 2018 5,438,072 $ 5.11 Granted 3,693,233 2.66 Exercised (100,000 ) 2.70 Cancelled (50,000 ) 2.33 Forfeited (27,778 ) 8.75 Outstanding at March 31, 2019 8,953,527 4.13 Options exercisable at March 31, 2019 5,488,325 $ 4.79 Weighted-average grant date fair value of options granted during the years ended March 31, 2019 and 2018 was $1.76 and $2.72, respectively. Stock Options Outstanding Stock Options Vested Range of Exercise Price Number Outstanding at March 31, 2019 Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Number Vested at March 31, 2019 Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value $2.06-$8.75 8,953,527 $ 4.13 7.89 $ — 5,488,325 $ 4.79 7.45 $ — The intrinsic value calculated as the excess of the market value of as March 31, 2019 over the exercise price of the options, is zero. The market value as of March 31, 2019 was $1.76 as reported by the NASDAQ Capital Market. The total intrinsic value of options exercised during the year ended March 31, 2019 was zero. Options Weighted Average Grant Date Fair Value Per Share Non-vested options at March 31, 2018 $ 2,548,210 $ 3.93 Granted 3,693,233 1.76 Vested (2,698,463 ) 3.08 Forfeited (27,778 ) 7.57 Cancelled (50,000 ) 1.52 Non-vested options at March 31, 2019 $ 3,465,202 $ 2.29 The fair value of options vested during the years ended March 31, 2019 and 2018 was $8,298,730 and $12,509,695, respectively.

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Note 12. Income Taxes. The Company provides for income taxes under ASC 740. Under ASC 740, the liability method is used in accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company has not recorded a current or deferred income tax expense or benefit since its inception. The Company’s loss before income taxes was $33.0 million and $19.0 million for the years ended March 31, 2019 and 2018, respectively, and was generated entirely in the United States. Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company’s deferred tax assets are comprised of the following: March 31, 2019 2018 Net operating loss carryforward $ 10,663,981 $ 5,736,229 Research and development credit carryforward 718,748 410,369 Stock options - NQSOs 4,518,506 2,759,122 Accruals and other temporary differences 864,789 757,567 Gross deferred tax assets 16,766,024 9,663,287 Deferred tax valuation allowance (16,766,024 ) (9,663,287 ) Net deferred taxes $ — $ — Based on the Company’s history of operating losses since inception and consideration of available positive and negative evidence, the Company has concluded that it is not more likely than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company continues to maintain a full valuation allowance against its net deferred tax assets as of March 31, 2019. The valuation allowance increased by $7.1 million for the year ended March 31, 2019 primarily due to the increase in the net operating loss carryforward and stock based compensation. A reconciliation of income tax benefit computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows: Year Ended March 31, 2019 2018 U.S. statutory income tax rate 21.0 % 31.5 % Stock options — (7.0 ) Permanent differences (0.8 ) 0.6 Tax rate change — (27.7 ) R&D credit carryforwards 1.3 0.5 Valuation allowance (21.5 ) 2.1 Effective tax rate — % — % Under the provisions of the Internal Revenue Code, the net operating loss (“NOL”) carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of a 50% cumulative change in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, as well as similar state tax provisions. This could limit the amount of NOLs that the Company can utilize annually to offset future taxable income or tax liabilities. The amount of the annual limitation, if any, will be determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has completed several financing transactions since its inception which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code, or could result in a change in control in the future. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: Year Ended March 31, 2019 2018 Gross unrecognized tax benefits at beginning of year $ 469,167 $ 617,233 Decreases for tax positions in prior period (396,749 ) (148,066 ) Increase for tax positions in current period 54,420 — Gross unrecognized tax benefits at end of year $ 126,838 $ 469,167 As of March 31, 2019, the Company had $126,838 of unrecognized tax benefits, which were offset with the net operating loss and valuation allowance on the consolidated balance sheet. None of the gross unrecognized tax benefits would affect the effective tax rate at March 31, 2019, if recognized. In addition, the Company did not record any penalties or interest related to uncertain tax positions for the periods presented in these consolidated financial statements. The Company does not have any positions for which it is reasonably possible that there will be significant increase or decrease in the amounts of unrecognized tax benefits within twelve months of the reporting date. The Company files income tax returns in the United States, and various state jurisdictions. The federal and state income tax returns are generally subject to tax examinations for the period January 1, 2015 through March 31, 2018. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state tax authorities to the extent utilized in a future period. The Company has completed the accounting for the tax impact of the Tax Cuts and Jobs Act (“the

Quarterly Information (unaudite

Quarterly Information (unaudited)	12 Months Ended
	Mar. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Quarterly Information (unaudited)	Note 13. Quarterly Information (unaudited) June 30, 2018 September 30, 2018 December 31, 2018 March 31, 2019 Fiscal Year Ended March 31, 2019 Operating expenses: Research and development $ 3,010,688 $ 3,443,516 $ 4,525,228 $ 3,740,049 General and administrative 3,708,481 3,569,174 3,550,223 3,758,287 Severance expense — — — 2,470,906 Total operating expenses 6,719,169 7,012,690 8,075,451 9,969,242 Loss from operations (6,719,169 ) (7,012,690 ) (8,075,451 ) (9,969,242 ) Warrant modification expense — — — (1,289,125 ) Other income (expense), net (3,627 ) (2,430 ) 27,497 61,122 Loss before income taxes (6,722,796 ) (7,015,120 ) (8,047,954 ) (11,197,245 ) Income tax expense — — — — Net loss $ (6,722,796 ) $ (7,015,120 ) $ (8,047,954 ) $ (11,197,245 ) Basic and diluted loss per common share $ (0.07 ) $ (0.07 ) $ (0.08 ) $ (0.10 ) Basic and diluted weighted average shares outstanding 101,226,479 101,647,555 103,009,449 103,546,379 June 30, 2017 September 30, 2017 December 31, 2017 March 31, 2018 Fiscal Year Ended March 31, 2018 Operating expenses: Research and development $ 1,264,358 $ 2,551,920 $ 2,585,991 $ 2,437,392 General and administrative 1,924,204 2,744,998 2,975,274 2,875,741 Total operating expenses 3,188,562 5,296,918 5,561,265 5,313,133 Loss from operations (3,188,562 ) (5,296,918 ) (5,561,265 ) (5,313,133 ) Other income 315,624 74,761 — — Loss before income taxes (2,872,938 ) (5,222,157 ) (5,561,265 ) (5,313,133 ) Income tax expense — — — — Net loss $ (2,872,938 ) $ (5,222,157 ) $ (5,561,265 ) $ (5,313,133 ) Basic and diluted loss per common share $ (0.03 ) $ (0.06 ) $ (0.06 ) $ (0.06 ) Basic and diluted weighted average shares outstanding 89,258,377 89,321,067 89,929,161 93,829,568

Subsequent Events

Subsequent Events	12 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	Note 14. Subsequent Events. The Company evaluates events or transactions that occur after the balance sheet date but prior to the issuance of consolidated financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. On April 2, 2019, the Company closed on an underwritten registered offering of 8,000,000 shares of its common stock, par value $0.0001 per share, and warrants to purchase up to 8,000,000 shares of its common stock with an exercise price of $2.00 per share at a combined purchase price of $1.50 per share of common stock and accompanying warrant. The net proceeds to the Company, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, was approximately $11 million.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).
Principles of Consolidation	Principles of Consolidation The Company’s consolidated financial statements include the accounts of Tyme Tech and its subsidiaries, Tyme, Inc. and Luminant. All intercompany transactions and balances have been eliminated in consolidation.
Risks and Uncertainties	Risks and Uncertainties The Company is subject to those risks associated with any specialty pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants, as well as third party contractors.
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Significant items subject to such estimation include the calculation of the stock-based compensation. Actual results could differ from such estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly-liquid investments that have maturities of three months or less when acquired to be cash equivalents. At March 31, 2019 and 2018, the Company did not have any cash equivalents. The Company’s cash and cash equivalents consisted of $14.3 million at March 31, 2019 and $29.0 million at March 31, 2018.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash. Cash is deposited with major banks and, at times, such balances with any one financial institution may be in excess of FDIC insurance limits. The Company exceeded the FDIC limit of $250,000 by $14.0 million at March 31, 2019 and $28.7 million at March 31, 2018. Although the Company has exceeded the federally insured limit, it has not incurred losses related to these deposits. Management monitors the Company’s accounts with these institutions to minimize credit risk.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments, including cash, accounts payable and other current liabilities approximates fair value given their short-term nature. The fair value of the severance payable approximates the carrying value, which represents the present value of future severance payments. The fair value of the derivative liability is discussed below. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value should be based on the assumptions that market participants would use when pricing an asset or liability and is based on a fair value hierarchy that prioritizes the information used to develop those assumptions. The fair value hierarchy gives the highest priority to quoted prices in active markets (observable inputs) and the lowest priority to the Company’s assumptions (unobservable inputs). Fair value measurements should be disclosed separately by level within the fair value hierarchy. For assets and liabilities recorded at fair value, it is the Company’s policy to maximize the use of observable inputs and minimize the use of unobservable inputs when developing fair value measurements, in accordance with established fair value hierarchy. Fair value measurements for assets and liabilities where there exists limited or no observable market data are based primarily upon estimates, and often are calculated based on the economic and competitive environment, the characteristics of the asset or liability and other factors. Therefore, the results cannot be determined with precision and may not be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any calculation technique, and changes in the underlying assumptions used, including discount rates and estimates of future cash flows, could significantly affect the results of current or future values. Additionally, from time to time, the Company may be required to record at fair value other assets on a nonrecurring basis, such as assets held for sale and certain other assets. These nonrecurring fair value adjustments typically involve application of lower-of-cost-or-market accounting or write-downs of individual assets. Fair value guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include: • Level 1 — Quoted prices in active markets for identical assets or liabilities. • Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 valuations are for instruments that are not traded in active markets or are subject to transfer restrictions and may be adjusted to reflect illiquidity and/or non-transferability, with such adjustment generally based on available market evidence. In the absence of such evidence, management’s best estimate is used. An adjustment to the pricing method used within either Level 1 or Level 2 inputs could generate a fair value measurement that effectively falls in a lower level in the hierarchy. The Company had no assets or liabilities classified as Level 1, Level 2, or Level 3 for the year ended March 31, 2019 and 2018. There were no transfers between Level 1, Level 2 and Level 3 in any of the periods reported. The changes in the fair value of the derivative liabilities for the year ended March 31, 2018 are as follows: Fair value at March 31, 2017 $ 378,600 Fair value of liability-classified anti-dilution feature 11,785 Change in fair value of derivative liability (390,385 ) Fair value at March 31, 2018 $ —
Prepaid and Other Current Assets	Prepaid and Other Current Assets Prepaid expenses represent expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time. Prepaid and other current assets includes $0.6 million and $0.5 million of prepaid insurance as of March 31, 2019 and 2018, respectively.
Property and Equipment, Net	Property and Equipment, Net Property and equipment are recorded at cost and are depreciated on a straight-line basis over their estimated useful lives. The Company estimates a life of five to seven years for equipment and furniture and fixtures. Upon sale or retirement, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss is reflected in results of operations. Repairs and maintenance costs are expensed as incurred.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company assesses the recoverability of its long-lived assets, which include fixed assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine whether the asset’s value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the years ended March 31, 2019 and 2018, the Company determined that there were no triggering events requiring an impairment analysis.
Research and Development	Research and Development Research and development costs are expensed as incurred and are primarily comprised of, but not limited to, external research and development expenses incurred under arrangements with third parties, such as contract research organizations (“CROs”), contract manufacturing organizations (“CMOs”) and consultants that conduct clinical and preclinical studies, costs associated with preclinical and development activities, costs associated with regulatory operations, depreciation expense for assets used in research and development activities and employee related expenses, including salaries and benefits for research and development personnel. Costs for certain development activities, such as clinical studies, are accrued, over the service period specified in the contract and recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors on their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which may differ from the patterns of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued expense.
Income Taxes	Income Taxes Income tax expense, deferred tax assets and liabilities, and liabilities for unrecognized tax benefits reflect management’s best estimate of current and future taxes to be paid. The Company is subject to income taxes in the United States, for federal and various state jurisdictions. Significant judgments and estimates are required in the determination of the income tax expense. Deferred income taxes arise from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements, which will result in taxable or deductible amounts in the future. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is provided when, after consideration of available positive and negative evidence that it is not more likely than not that the benefit from deferred tax assets will be realizable. In recognition of this risk, we have provided a full valuation allowance against the net deferred tax assets. The assumptions about future taxable income require the use of significant judgment and are consistent with the plans and estimates we are using to manage the underlying businesses. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). The calculation of tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in various jurisdictions. ASC 740 “Income Taxes” states that a tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits. When and if the Company were to recognize interest and penalties related to unrecognized tax benefits, they would be reported in tax expense.
Segment Information	Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment.
Derivative Liabilities	Derivative Liabilities Accounting standards require presentation of derivative liabilities at fair value. Derivative liabilities are adjusted to reflect fair value at the end of each reporting period, with any change in the fair value being recorded in results of operations as a component of other income or expense. Derivative Liability - PPO The Company had recorded a derivative liability related to an anti-dilution provision as part of a 2014 financing agreement. That anti-dilution provision was determined to be a freestanding financial instrument that was carried as a liability at fair value of $0.4 million. During the year ended March 31, 2018 the anti-dilution provision expired without the triggering of any such protection. Accordingly, as of March 31, 2018 and thereafter, there was no fair value of the derivative liability .
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share The Company calculates net loss per share in accordance with ASC Topic 260, “Earning per Share.” Basic net loss per share is computed by dividing net loss attributable to the Company by the weighted average number of shares of Company common stock outstanding for the period, and diluted earnings per share is computed by including common stock equivalents outstanding for the period. During the periods presented, the calculation excludes any potential dilutive common shares and any equivalents as they would have been anti-dilutive as the Company incurred losses for the periods then ended.
Stock-based Compensation	Stock-based Compensation The Company follows the authoritative guidance for accounting for stock-based compensation in ASC 718, Compensation-Stock Compensation. The guidance requires that stock-based payment transactions be recognized in the financial statements based on their fair value at the grant date and recognized as compensation expense over the vesting period as services are being provided. (See Note 11, Equity Incentive Plan.) The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. The use of the Black-Scholes option pricing model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected The Company accounted for stock-based awards issued to non-employees in accordance with ASC 505-50, “Equity-Based Payment to Non-Employees” and accordingly the fair value of the stock options granted to non-employees was remeasured each reporting period until the earlier of: a) the performance commitment date, or b) the date the services required under the arrangement have been completed and the resulting increase or decrease in value, if any, was recognized as expense or income, respectively, during the period the related services are rendered. Effective July 1, 2018, the Company adopted ASU 2018-07 and, as such, the fair value options granted to non-employees is estimated at the date of grant only.
Reclassification	Reclassification Certain prior year amounts have been reclassified to conform to the current year presentation.
Recent Accounting Pronouncements	Recently Adopted Accounting Pronouncements In June 2018, the FASB issued ASU 2018-07, which simplifies the accounting for share-based payments made to nonemployees so that the accounting for such payments is substantially the same as those made to employees, with certain exceptions. Under this ASU, equity-classified share based awards to nonemployees will be measured at fair value on the grant date of the awards, entities will need to assess the probability of satisfying performance conditions if any are present, and awards will continue to be classified according to ASC 718 upon vesting which eliminates the need to reassess classification upon vesting, consistent with awards granted to employees, unless the award is modified after the service has been rendered, any other conditions necessary to earn the right to benefit from the instruments have been satisfied, and the nonemployee is no longer providing services. The Company elected to early adopt ASU 2018-07 effective July 1, 2018. In May 2017, the FASB issued ASU No. 2017-09, Compensation-Stock Compensation (Topic 718) - Scope of Modification Accounting In February 2017, the FASB issued Update No. 2017-05, Other Income-Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets In January 2017, the FASB issued ASU 2017-01, amending Business Combinations: Clarifying the Definition of a Business In January 2016, the FASB issued ASU No. 2016-01, Financial Instruments - Overall (Subtopic 825-10), Recognition and Measurement of Financial Assets and Financial Liabilities Recent Accounting Pronouncements In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842)

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Schedule of Changes in Fair Value Derivative Liability	The changes in the fair value of the derivative liabilities for the year ended March 31, 2018 are as follows: Fair value at March 31, 2017 $ 378,600 Fair value of liability-classified anti-dilution feature 11,785 Change in fair value of derivative liability (390,385 ) Fair value at March 31, 2018 $ —

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	12 Months Ended
	Mar. 31, 2019
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of basic and diluted net loss per common share for the periods indicated: Year Ended March 31, 2019 2018 Basic and diluted net loss per common share calculation Net loss $ (32,983,115 ) $ (18,969,493 ) Weighted average common shares outstanding — basic and diluted 102,354,050 90,567,476 Net loss per share of common stock — basic and diluted $ (0.32 ) $ (0.21 )
Schedule of Anti-dilutive Shares Outstanding	The following outstanding securities at March 31, 2019 and 2018 have been excluded from the computation of diluted weighted average shares outstanding, as they would have been anti-dilutive: Year Ended March 31, 2019 2018 Stock options 8,953,527 5,438,072 Warrants 4,499,603 5,585,874 Total 13,453,130 11,023,946

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Mar. 31, 2019
Property Plant And Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment, net consisted of the following: March 31, 2019 March 31, 2018 Machinery and equipment $ 37,007 $ 21,463 Less: accumulated depreciation 26,644 18,224 $ 10,363 $ 3,239

Accounts Payable and Other Cu_2

Accounts Payable and Other Current Liabilities (Tables)	12 Months Ended
	Mar. 31, 2019
Payables And Accruals [Abstract]
Schedule of Accounts Payable and Other Current Liabilities	Accounts payable and other current liabilities consisted of the following: March 31, 2019 March 31, 2018 Legal $ 602,129 $ 421,261 Consultant and professional services 170,257 134,324 Accounting and auditing 331,119 81,652 Research and development 1,907,787 1,678,675 Board of Directors and Scientific Advisory Board Compensation 489,393 442,610 Other 191,623 58,568 $ 3,692,308 $ 2,817,090

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Schedule of Common Stock Warrant Activity	The following summarizes the common stock warrant activity for the years ended March 31, 2019 and March 31, 2018: Warrant Shares of Common Stock Weighted Average Exercise Price Outstanding at March 31, 2017 4,526,271 $ 3.42 Granted 1,069,603 3.00 Exercised (10,000 ) 3.00 Cancelled — — Outstanding at March 31, 2018 5,585,874 3.34 Granted — — Exercised (1,086,271 ) 3.00 Cancelled — — Outstanding at March 31, 2019 4,499,603 $ 3.42

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)	12 Months Ended
	Mar. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Assumptions Utilized to Estimate the Fair Value of Stock Options Granted	The assumptions utilized to estimate the fair value of stock options granted are presented in the following table: Year Ended March 31, 2019 2018 Risk free interest rate 2.24%-3.10% 1.74%-2.70% Expected volatility 71.86%-76.31% 65.95%-90.32% Expected term 3-6.5 years 1-10 years Dividend yield 0.0% 0.0%
Schedule of Stock Options	The following is a summary of the activity of the Company’s stock options under the 2015 Plan and 2016 Director Plan as of March 31, 2019: Number of Options Weighted Average Exercise Price Outstanding at March 31, 2018 5,438,072 $ 5.11 Granted 3,693,233 2.66 Exercised (100,000 ) 2.70 Cancelled (50,000 ) 2.33 Forfeited (27,778 ) 8.75 Outstanding at March 31, 2019 8,953,527 4.13 Options exercisable at March 31, 2019 5,488,325 $ 4.79
Schedule of Stock Option by Exercise Price Range	Stock Options Outstanding Stock Options Vested Range of Exercise Price Number Outstanding at March 31, 2019 Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value Number Vested at March 31, 2019 Weighted Average Exercise Price Weighted Average Remaining Life (Years) Aggregate Intrinsic Value $2.06-$8.75 8,953,527 $ 4.13 7.89 $ — 5,488,325 $ 4.79 7.45 $ —
Schedule of Non-vested Options	Options Weighted Average Grant Date Fair Value Per Share Non-vested options at March 31, 2018 $ 2,548,210 $ 3.93 Granted 3,693,233 1.76 Vested (2,698,463 ) 3.08 Forfeited (27,778 ) 7.57 Cancelled (50,000 ) 1.52 Non-vested options at March 31, 2019 $ 3,465,202 $ 2.29

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets	The significant components of the Company’s deferred tax assets are comprised of the following: March 31, 2019 2018 Net operating loss carryforward $ 10,663,981 $ 5,736,229 Research and development credit carryforward 718,748 410,369 Stock options - NQSOs 4,518,506 2,759,122 Accruals and other temporary differences 864,789 757,567 Gross deferred tax assets 16,766,024 9,663,287 Deferred tax valuation allowance (16,766,024 ) (9,663,287 ) Net deferred taxes $ — $ —
Schedule of Reconciliation of Income Tax Benefit	A reconciliation of income tax benefit computed at the statutory federal income tax rate to income taxes as reflected in the financial statements is as follows: Year Ended March 31, 2019 2018 U.S. statutory income tax rate 21.0 % 31.5 % Stock options — (7.0 ) Permanent differences (0.8 ) 0.6 Tax rate change — (27.7 ) R&D credit carryforwards 1.3 0.5 Valuation allowance (21.5 ) 2.1 Effective tax rate — % — %
Schedule of Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: Year Ended March 31, 2019 2018 Gross unrecognized tax benefits at beginning of year $ 469,167 $ 617,233 Decreases for tax positions in prior period (396,749 ) (148,066 ) Increase for tax positions in current period 54,420 — Gross unrecognized tax benefits at end of year $ 126,838 $ 469,167

Quarterly Information (unaudi_2

Quarterly Information (unaudited) (Tables)	12 Months Ended
	Mar. 31, 2019
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Information (unaudited)	June 30, 2018 September 30, 2018 December 31, 2018 March 31, 2019 Fiscal Year Ended March 31, 2019 Operating expenses: Research and development $ 3,010,688 $ 3,443,516 $ 4,525,228 $ 3,740,049 General and administrative 3,708,481 3,569,174 3,550,223 3,758,287 Severance expense — — — 2,470,906 Total operating expenses 6,719,169 7,012,690 8,075,451 9,969,242 Loss from operations (6,719,169 ) (7,012,690 ) (8,075,451 ) (9,969,242 ) Warrant modification expense — — — (1,289,125 ) Other income (expense), net (3,627 ) (2,430 ) 27,497 61,122 Loss before income taxes (6,722,796 ) (7,015,120 ) (8,047,954 ) (11,197,245 ) Income tax expense — — — — Net loss $ (6,722,796 ) $ (7,015,120 ) $ (8,047,954 ) $ (11,197,245 ) Basic and diluted loss per common share $ (0.07 ) $ (0.07 ) $ (0.08 ) $ (0.10 ) Basic and diluted weighted average shares outstanding 101,226,479 101,647,555 103,009,449 103,546,379 June 30, 2017 September 30, 2017 December 31, 2017 March 31, 2018 Fiscal Year Ended March 31, 2018 Operating expenses: Research and development $ 1,264,358 $ 2,551,920 $ 2,585,991 $ 2,437,392 General and administrative 1,924,204 2,744,998 2,975,274 2,875,741 Total operating expenses 3,188,562 5,296,918 5,561,265 5,313,133 Loss from operations (3,188,562 ) (5,296,918 ) (5,561,265 ) (5,313,133 ) Other income 315,624 74,761 — — Loss before income taxes (2,872,938 ) (5,222,157 ) (5,561,265 ) (5,313,133 ) Income tax expense — — — — Net loss $ (2,872,938 ) $ (5,222,157 ) $ (5,561,265 ) $ (5,313,133 ) Basic and diluted loss per common share $ (0.03 ) $ (0.06 ) $ (0.06 ) $ (0.06 ) Basic and diluted weighted average shares outstanding 89,258,377 89,321,067 89,929,161 93,829,568

Nature of Business - Additional

Nature of Business - Additional Information (Detail) - USD ($)	Apr. 02, 2019	Apr. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2019	Mar. 31, 2018	Nov. 02, 2017
Nature Of Business [Line Items]
Gross proceeds from issuance of common stock											$ 5,800,000
Cash proceeds from private placement											$ 5,668,244	$ 5,824,017
Aggregate offering													$ 30,000,000
Common stock, par value			$ 0.0001				$ 0.0001				$ 0.0001	$ 0.0001	$ 0.0001
Available for offering			$ 17,900,000								$ 17,900,000
Net cash used in operating activities											(20,116,101)	$ (11,879,260)
Net loss			(11,197,245)	$ (8,047,954)	$ (7,015,120)	$ (6,722,796)	$ (5,313,133)	$ (5,561,265)	$ (5,222,157)	$ (2,872,938)	(32,983,115)	(18,969,493)
Non-cash expense											10,200,000
Working capital			$ 9,800,000								9,800,000
Subsequent Event [Member]
Nature Of Business [Line Items]
Common stock, par value	$ 0.0001
Maximum [Member]
Nature Of Business [Line Items]
Aggregate offering													$ 30,000,000
Underwriters Public Offering [Member] | Subsequent Event [Member]
Nature Of Business [Line Items]
Cash proceeds from private placement	$ 11,000,000	$ 11,300,000
ATM Financing Facility [Member]
Nature Of Business [Line Items]
Gross proceeds from issuance of common stock											5,800,000	6,200,000
Offering expense											$ 175,306	$ 327,939

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Detail)	12 Months Ended
	Mar. 31, 2019USD ($)Number	Mar. 31, 2018USD ($)	Mar. 31, 2017USD ($)
Significant Accounting Policies [Line Items]
Cash equivalents	$ 0	$ 0
Cash and cash equivalents	14,302,328	28,975,822	$ 10,482,977
Cash in excess of FDIC insured limit of $250000 amount	$ 14,000,000	28,700,000
Number of operating segment | Number	1
Fair value of derivative liability		0	$ 400,000
Minimum [Member] | Equipment [Member]
Significant Accounting Policies [Line Items]
Useful life	5 years
Minimum [Member] | Furniture and Fixtures [Member]
Significant Accounting Policies [Line Items]
Useful life	5 years
Maximum [Member] | Equipment [Member]
Significant Accounting Policies [Line Items]
Useful life	7 years
Maximum [Member] | Furniture and Fixtures [Member]
Significant Accounting Policies [Line Items]
Useful life	7 years
Prepaid and Other Current Assets [Member]
Significant Accounting Policies [Line Items]
Prepaid insurance	$ 600,000	$ 500,000

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Changes in Fair Value Derivative Liability (Detail)	12 Months Ended
	Mar. 31, 2018USD ($)
Debt Instrument Fair Value Carrying Value [Abstract]
Fair value at March 31, 2017	$ 378,600
Fair value of liability-classified anti-dilution feature	11,785
Change in fair value of derivative liability	(390,385)
Fair value at March 31, 2018	$ 0

Net Loss Per Common Share - Sch

Net Loss Per Common Share - Schedule of Basic and Diluted Net Loss Per Share (Detail) - USD ($)	3 Months Ended								12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2019	Mar. 31, 2018
Basic and diluted net loss per common share calculation
Net loss	$ (11,197,245)	$ (8,047,954)	$ (7,015,120)	$ (6,722,796)	$ (5,313,133)	$ (5,561,265)	$ (5,222,157)	$ (2,872,938)	$ (32,983,115)	$ (18,969,493)
Weighted average common shares outstanding — basic and diluted	103,546,379	103,009,449	101,647,555	101,226,479	93,829,568	89,929,161	89,321,067	89,258,377	102,354,050	90,567,476
Net loss per share of common stock — basic and diluted	$ (0.10)	$ (0.08)	$ (0.07)	$ (0.07)	$ (0.06)	$ (0.06)	$ (0.06)	$ (0.03)	$ (0.32)	$ (0.21)

Net Loss Per Common Share - S_2

Net Loss Per Common Share - Schedule of Anti-dilutive Shares Outstanding (Detail) - shares	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	13,453,130	11,023,946
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	8,953,527	5,438,072
Warrant [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total	4,499,603	5,585,874

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment (Detail) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Less: accumulated depreciation	$ 26,644	$ 18,224
Property and equipment, net	10,363	3,239
Machinery and Equipment [Member]
Property and equipment, gross	$ 37,007	$ 21,463

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Detail) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Property Plant And Equipment [Abstract]
Depreciation expense	$ 8,420	$ 4,296

Accounts Payable and Other Cu_3

Accounts Payable and Other Current Liabilities - Schedule of Accounts Payable and Other Current Liabilities (Detail) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Payables And Accruals [Abstract]
Legal	$ 602,129	$ 421,261
Consultant and professional services	170,257	134,324
Accounting and auditing	331,119	81,652
Research and development	1,907,787	1,678,675
Board of Directors and Scientific Advisory Board Compensation	489,393	442,610
Other	191,623	58,568
Total	$ 3,692,308	$ 2,817,090

Severance Payable - Additional

Severance Payable - Additional Information (Detail)	3 Months Ended	12 Months Ended
	Mar. 31, 2019USD ($)	Mar. 31, 2019USD ($)
Severance Payable [Line Items]
Salary continuance term		5 years
Reimbursement of health benefits term		3 years
Severance expense	$ 2,470,906	$ 2,470,906
Discount rate	6.00%	6.00%
Stock option modification expense		$ 400,000
Severance liability	$ 2,100,000	$ 2,100,000
Minimum [Member]
Severance Payable [Line Items]
Post-termination exercise period		3 months
Maximum [Member]
Severance Payable [Line Items]
Post-termination exercise period		5 years

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
License Agreement [Line Items]
Remaining insurance note payable	$ 597,339	$ 480,094
Insurance Note Payable [Member]
License Agreement [Line Items]
Principal amount	600,000	500,000
Remaining insurance note payable	$ 600,000	$ 500,000
Maturity period	March 31, 2019 and 2018

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail)	Mar. 15, 2019shares	Mar. 10, 2017USD ($)$ / sharesshares	Apr. 30, 2017USD ($)$ / sharesshares	Mar. 31, 2019USD ($)$ / sharesshares	Mar. 31, 2019USD ($)$ / sharesshares	Mar. 31, 2018USD ($)$ / sharesshares	Nov. 02, 2017USD ($)$ / shares	Mar. 31, 2017$ / sharesshares
Class Of Warrant Or Right [Line Items]
Preferred stock, authorized				10,000,000	10,000,000	10,000,000
Preferred stock, par value | $ / shares				$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock, issued				0	0	0
Preferred stock, outstanding				0	0	0
Warrant modification expense | $				$ 1,289,125	$ 1,289,125
Common stock, par value (in dollars per share) | $ / shares				$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Aggregate offering | $							$ 30,000,000
Gross proceeds from issuance of common stock | $					$ 5,800,000
Available for offering | $				$ 17,900,000	17,900,000
Gross proceeds through public offering | $					$ 5,668,244	$ 5,824,017
Maximum [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, term				1 year	1 year
Aggregate offering | $							$ 30,000,000
Minimum [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, term				6 months 15 days	6 months 15 days
Fair Value of Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input | $ / shares				2.31	2.31
Expected Volatility [Member] | Maximum [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input				0.87	0.87
Expected Volatility [Member] | Minimum [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input				0.84	0.84
Dividend Yield [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input				0	0
Risk-free Interest Rate [Member] | Maximum [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input				0.0252	0.0252
Risk-free Interest Rate [Member] | Minimum [Member]
Class Of Warrant Or Right [Line Items]
Warrants and rights outstanding, measurement input				0.0246	0.0246
Warrant [Member]
Class Of Warrant Or Right [Line Items]
Exercise price | $ / shares				$ 3.42	$ 3.42	$ 3.34		$ 3.42
Warrants outstanding				4,499,603	4,499,603	5,585,874		4,526,271
Exercise of warrants					1,086,271	10,000
Issuance of shares					235,685
March 2017 Private Placement [Member]
Class Of Warrant Or Right [Line Items]
Total gross proceeds from private placement | $		$ 9,200,000
Number of shares issued upon new issue		3,588,620
Warrants outstanding	3,245,288
Warrants, extended expiration date	Sep. 30, 2019
March 2017 Private Placement [Member] | Warrant [Member]
Class Of Warrant Or Right [Line Items]
Number of shares issued upon new issue		3,588,620
Exercise price | $ / shares		$ 3
Vesting period		2 years
April 2017 Private Placement [Member]
Class Of Warrant Or Right [Line Items]
Total gross proceeds from private placement | $			$ 2,700,000
Number of shares issued upon new issue			1,069,603
Warrants outstanding	238,233
Warrants, extended expiration date	Sep. 30, 2019
April 2017 Private Placement [Member] | Warrant [Member]
Class Of Warrant Or Right [Line Items]
Number of shares issued upon new issue			1,069,603
Exercise price | $ / shares			$ 3
Vesting period			2 years
Private Placement Offering [Member] | Warrant [Member] | Securities Purchase Agreement [Member]
Class Of Warrant Or Right [Line Items]
Common stock purchase warrants outstanding and excercisable				4,469,836	4,469,836
ATM Financing Facility [Member]
Class Of Warrant Or Right [Line Items]
Number of shares issued upon new issue					2,383,884	1,543,364
Gross proceeds from issuance of common stock | $					$ 5,800,000	$ 6,200,000
Related cost offset the proceeds | $					$ 200,000	$ 300,000
Public Offering [Member]
Class Of Warrant Or Right [Line Items]
Number of shares issued upon new issue						10,350,000
Gross proceeds through public offering | $						$ 23,300,000

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Common Stock Warrant Activity (Detail) - Warrant [Member] - $ / shares	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Class Of Warrant Or Right [Line Items]
Warrant Shares of Common Stock, Outstanding at beginning	5,585,874	4,526,271
Warrant Shares of Common Stock, Granted		1,069,603
Warrant Shares of Common Stock, Exercised	(1,086,271)	(10,000)
Warrant Shares of Common Stock, Outstanding at ending	4,499,603	5,585,874
Weighted Average Exercise Price, Outstanding at beginning	$ 3.34	$ 3.42
Weighted Average Exercise Price, Granted		3
Weighted Average Exercise Price, Exercised	3	3
Weighted Average Exercise Price, Outstanding at ending	$ 3.42	$ 3.34

Commitment and Contingencies -

Commitment and Contingencies - Additional Information (Detail)	1 Months Ended	6 Months Ended		12 Months Ended
	May 31, 2019USD ($)	Mar. 31, 2019USD ($)	Sep. 30, 2018USD ($)	Mar. 31, 2019USD ($)Contract	Mar. 31, 2018USD ($)
Commitment And Contingencies [Line Items]
Number of contracts | Contract				3
Contractual obligation		$ 2,000,000		$ 2,000,000
New Jersey [Member] | Office Space [Member]
Commitment And Contingencies [Line Items]
Lease term contract		2 years		2 years
Monthly rent		$ 4,292	$ 2,289
Operating lease, remaining expiration term				2021-02
Future rent payments, 2020		40,000		$ 40,000
Future rent payments, 2021		$ 47,000		$ 47,000
New Jersey [Member] | Office Furniture [Member]
Commitment And Contingencies [Line Items]
Lease term contract		2 years		2 years
Future rent payments, 2020		$ 19,000		$ 19,000
Future rent payments, 2021		$ 17,000		17,000
New York [Member] | Office Space [Member]
Commitment And Contingencies [Line Items]
Rent expense				$ 243,000	$ 93,000
Subsequent Event [Member]
Commitment And Contingencies [Line Items]
Increase in purchase commitment	$ 495,000

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - Drinker, Biddle & Reath LLP ("DBR") [Member] - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Legal expenses	$ 1,000,000	$ 1,800,000
Capitalized legal expenses		200,000
Accounts payable and accrued expenses payable	$ 325,000	$ 384,000

Equity Incentive Plan - Additio

Equity Incentive Plan - Additional Information (Detail) - USD ($)	Aug. 23, 2018	Mar. 05, 2015	Feb. 28, 2018	Mar. 31, 2019	Mar. 31, 2018
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]
Unrecognized compensation expense				$ 7,300,000	$ 9,600,000
Unrecognized compensation expense recognition period				1 year 2 months 12 days
Allocated compensation expense				$ 9,000,000	$ 7,700,000
Grant date fair value of options granted				$ 1.76	$ 2.72
Fair value of options vested				$ 8,298,730	$ 12,509,695
Severance Expense [Member]
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]
Allocated compensation expense				400,000
General and Administrative Expense [Member]
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]
Allocated compensation expense				5,700,000	4,100,000
Research and development expense [Member]
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]
Allocated compensation expense				$ 2,900,000	$ 3,600,000
2015 Equity Incentive Plan [Member]
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]
Maximum number of awards issued		3,333,333
Percentage of fair market value on date of grant		100.00%
Award expiration period		10 years
Equity incentive plan, available percentage of common stock share issued and outstanding			12.50%
Number of shares available for grants				5,262,531
2016 Director Plan [Member]
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]
Increase in total number of common shares authorized	2,000,000
Number of common shares authorized	2,750,000
Number of shares available for initial grants	100,000
Annual grants stock option granted in future	50,000
Initial grants term	10 years
Annual grants term	10 years
Initial grants vesting period	1 year
Annual grants vesting period	1 year
Number of shares available for grants				1,425,150
Term of stock option awards	(i) increased the total number of shares of Common Stock authorized and reserved for issuance under the 2016 Director Plan by 2,000,000 shares to 2,750,000 shares: (ii) made “Initial Grants” upon a director’s initial appointment to the Board consisting of an immediate stock option grant of 100,000 shares at fair market value; and (iii) made “Annual Grants” for members who continue in service as members of the Board subsequent to each annual meeting of stockholders occurring subsequent to an Initial Grant, an annual stock option grant of 50,000 shares at fair market value. The Initial Grants and Annual Grants have a ten year term, subject to applicable termination or forfeiture provisions, and vest in equal quarterly increments over a one-year period from the date of grant. As of March 31, 2019, there were 1,425,150 shares available for grant under the 2016 Director Plan.
Equity Incentive Plan 2015 and 2016 [Member]
Employee Stock Ownership Plan (ESOP) Disclosures [Line Items]
Aggregate intrinsic value, options				$ 0
Share price (in dollars per share)				$ 1.76
Intrinsic value of the exercised option				$ 0

Equity Incentive Plan - Schedul

Equity Incentive Plan - Schedule of Assumptions Utilized to Estimate the Fair Value of Stock Options Granted (Detail)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Summary Of Stock Option Activities [Line Items]
Dividend yield	0.00%	0.00%
Minimum [Member]
Summary Of Stock Option Activities [Line Items]
Risk free interest rate	2.24%	1.74%
Expected volatility	71.86%	65.95%
Expected term	3 years	1 year
Maximum [Member]
Summary Of Stock Option Activities [Line Items]
Risk free interest rate	3.10%	2.70%
Expected volatility	76.31%	90.32%
Expected term	6 years 6 months	10 years

Equity Incentive Plan - Sched_2

Equity Incentive Plan - Schedule of Stock Options (Detail)	12 Months Ended
	Mar. 31, 2019$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning | shares	5,438,072
Granted | shares	3,693,233
Exercised | shares	(100,000)
Cancelled | shares	(50,000)
Forfeited | shares	(27,778)
Outstanding at ending | shares	8,953,527
Options exercisable | shares	5,488,325
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning | $ / shares	$ 5.11
Granted | $ / shares	2.66
Exercised | $ / shares	2.70
Cancelled | $ / shares	2.33
Forfeited | $ / shares	8.75
Outstanding at ending | $ / shares	4.13
Options exercisable | $ / shares	$ 4.79

Equity Incentive Plan - Sched_3

Equity Incentive Plan - Schedule of Stock Option by Exercise Price Range (Detail) - Exercise Price $2.06 - $8.75 [Member]	12 Months Ended
	Mar. 31, 2019USD ($)$ / sharesshares
Stock Options Outstanding
Range of Exercise Price, Lower Limit	$ 2.06
Range of Exercise Price, Upper Limit	$ 8.75
Number Outstanding | shares	8,953,527
Weighted Average Exercise Price	$ 4.13
Weighted Average Remaining Life (Years)	7 years 10 months 20 days
Aggregate Intrinsic Value | $	$ 0
Stock Options Vested
Stock Options Vested | shares	5,488,325
Weighted Average Exercise Price	$ 4.79
Weighted Average Remaining Life (Years)	7 years 5 months 19 days
Aggregate Intrinsic Value | $	$ 0

Equity Incentive Plan - Sched_4

Equity Incentive Plan - Schedule of Non-vested Options (Detail) - $ / shares	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]
Non-vested options at beginning	2,548,210
Granted	3,693,233
Vested	(2,698,463)
Forfeited	(27,778)
Cancelled	(50,000)
Non-vested options at ending	3,465,202	2,548,210
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Non-vested options at beginning	$ 3.93
Granted	1.76	$ 2.72
Vested	3.08
Forfeited	7.57
Cancelled	1.52
Non-vested options at ending	$ 2.29	$ 3.93

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended								12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Loss before income taxes	$ (11,197,245)	$ (8,047,954)	$ (7,015,120)	$ (6,722,796)	$ (5,313,133)	$ (5,561,265)	$ (5,222,157)	$ (2,872,938)	$ (32,983,115)	$ (18,969,493)
Increase (decrease) in valuation allowance									7,100,000
Gross federal net operating loss carryforwards	50,800,000								50,800,000
Gross federal research and development tax credit carryforwards	800,000								800,000
Gross unrecognized tax benefits	$ 126,838				$ 469,167				126,838	$ 469,167	$ 617,233
Provisional income tax									$ 0

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets (Detail) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Net operating loss carryforward	$ 10,663,981	$ 5,736,229
Research and development credit carryforward	718,748	410,369
Stock options - NQSOs	4,518,506	2,759,122
Accruals and other temporary differences	864,789	757,567
Gross deferred tax assets	16,766,024	9,663,287
Deferred tax valuation allowance	(16,766,024)	(9,663,287)
Net deferred taxes	$ 0	$ 0

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Income Tax Benefit (Detail)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Tax Disclosure [Abstract]
U.S. statutory income tax rate	21.00%	31.50%
Stock options		(7.00%)
Permanent differences	(0.80%)	0.60%
Tax rate change		(27.70%)
R&D credit carryforwards	1.30%	0.50%
Valuation allowance	(21.50%)	2.10%
Effective tax rate	0.00%	0.00%

Income Taxes - Schedule of Unre

Income Taxes - Schedule of Unrecognized Tax Benefits (Detail) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Gross unrecognized tax benefits at beginning of year	$ 469,167	$ 617,233
Decreases for tax positions in prior period	(396,749)	(148,066)
Increase for tax positions in current period	54,420
Gross unrecognized tax benefits at end of year	$ 126,838	$ 469,167

Quarterly Information (unaudi_3

Quarterly Information (unaudited) - Schedule of Quarterly Information (unaudited) (Detail) - USD ($)	3 Months Ended								12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2019	Mar. 31, 2018
Operating expenses:
Research and development	$ 3,740,049	$ 4,525,228	$ 3,443,516	$ 3,010,688	$ 2,437,392	$ 2,585,991	$ 2,551,920	$ 1,264,358	$ 14,719,481	$ 8,839,661
General and administrative	3,758,287	3,550,223	3,569,174	3,708,481	2,875,741	2,975,274	2,744,998	1,924,204	14,586,165	10,520,217
Severance expense	2,470,906								2,470,906
Total operating expenses	9,969,242	8,075,451	7,012,690	6,719,169	5,313,133	5,561,265	5,296,918	3,188,562	31,776,552	19,359,878
Loss from operations	(9,969,242)	(8,075,451)	(7,012,690)	(6,719,169)	(5,313,133)	(5,561,265)	(5,296,918)	(3,188,562)	(31,776,552)	(19,359,878)
Warrant modification expense	(1,289,125)								(1,289,125)
Other income (expense), net	61,122	27,497	(2,430)	(3,627)					82,562	390,385
Other income							74,761	315,624
Loss before income taxes	(11,197,245)	(8,047,954)	(7,015,120)	(6,722,796)	(5,313,133)	(5,561,265)	(5,222,157)	(2,872,938)	(32,983,115)	(18,969,493)
Income tax expense	0	0	0	0	0	0	0	0
Net loss	$ (11,197,245)	$ (8,047,954)	$ (7,015,120)	$ (6,722,796)	$ (5,313,133)	$ (5,561,265)	$ (5,222,157)	$ (2,872,938)	$ (32,983,115)	$ (18,969,493)
Basic and diluted loss per common share	$ (0.10)	$ (0.08)	$ (0.07)	$ (0.07)	$ (0.06)	$ (0.06)	$ (0.06)	$ (0.03)	$ (0.32)	$ (0.21)
Basic and diluted weighted average shares outstanding	103,546,379	103,009,449	101,647,555	101,226,479	93,829,568	89,929,161	89,321,067	89,258,377	102,354,050	90,567,476

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($)	Apr. 02, 2019	Apr. 30, 2019	Mar. 31, 2019	Mar. 31, 2018	Nov. 02, 2017
Subsequent Event [Line Items]
Common stock, par value (in dollars per share)			$ 0.0001	$ 0.0001	$ 0.0001
Proceeds from underwritten registered offering, net of underwriting discounts and commissions			$ 5,668,244	$ 5,824,017
Subsequent Event [Member]
Subsequent Event [Line Items]
Issuance of common stock (in shares)	8,000,000
Common stock, par value (in dollars per share)	$ 0.0001
Exercise price	2
Combined purchase price of common stock and warrants	$ 1.50
Subsequent Event [Member] | Underwriters Public Offering [Member]
Subsequent Event [Line Items]
Proceeds from underwritten registered offering, net of underwriting discounts and commissions	$ 11,000,000	$ 11,300,000
Subsequent Event [Member] | Maximum [Member]
Subsequent Event [Line Items]
Number of shares that can be purchased with warrants	8,000,000